Active In-House Clinical Development and Out-Licensing to Pharmaceutical Companies
First written in FY2021. 6 of 14 entries say "Restated". Latest entry: 2026-08-13.
3 other companies' latest entry also says "Restated".
- FY2026SoftenedAnnual report
「During the fiscal year, we aimed to out-license PPMX-T002 and PPMX-T003, but were unable to achieve this. We will continue our efforts to out-license them as soon as possible.」
The company did not achieve its out-licensing target for PPMX-T002 and PPMX-T003 during the fiscal year, and now states that it will continue efforts toward early out-licensing without specifying a deadline. - FY2026-H1RestatedAnnual report
「We are continuing research and development to maximize the value of PPMX-T003 while also continuing our efforts toward early out-licensing.」
The company is continuing efforts to maximize the value of PPMX-T003 through research and development and to achieve early out-licensing. - FY2025SoftenedAnnual report
「During the fiscal year, we aimed to out-license PPMX-T002 and PPMX-T003, but were unable to achieve this. We will continue our efforts to out-license them as soon as possible.」
The company did not achieve its out-licensing target for PPMX-T002 and PPMX-T003 during the fiscal year, and now states that it will continue efforts toward early out-licensing without specifying a deadline. - FY2025-H1AdvancedAnnual report
「Accordingly, we first designated polycythemia vera (PV), a disease characterized by an abnormal increase in red blood cells, as the target indication and conducted a Phase 1 trial in Japan, which ended in June 2024. As of the date of filing this document, all data from the trial have been locked, and we are preparing the clinical study report.」
The Phase 1 trial of PPMX-T003 for PV ended in June 2024, and the company has progressed to preparing the clinical study report after locking all data. - FY2024AdvancedAnnual report
「The trial involving the remaining 1 patient is scheduled to end at the end of July 2024, and we aim to out-license the program in the fiscal year ending March 2025.」
In addition to the planned completion of the PPMX-T003 PV patient trial, the company has specified its target of out-licensing in the fiscal year ending March 2025. - FY2023RestatedAnnual report
「To deliver antibody drugs to patients as soon as possible, we will actively conduct clinical trials in-house and promote out-licensing to pharmaceutical companies.」
The company has reaffirmed its policy of conducting clinical trials in-house to enhance pipeline value before out-licensing to pharmaceutical companies. - FY2022RestatedAnnual report
「To deliver antibody drugs to patients as soon as possible, we will actively conduct clinical trials in-house and promote out-licensing to pharmaceutical companies.」
The company has reaffirmed its policy of conducting clinical trials in-house to enhance pipeline value before out-licensing to pharmaceutical companies. - FY2021First statedAnnual report
「To deliver antibody drugs to patients as soon as possible, we will actively conduct clinical trials in-house and promote out-licensing to pharmaceutical companies.」
The company has stated its policy of conducting in-house clinical trials to enhance pipeline value before out-licensing, rather than out-licensing solely at the preclinical stage.